In a recent study, Ladroue et al.18 proposed a two way classification for the pathogenic risk related to PHD2 mutations, with class I addressing mutations promoting a weak HIF-1α deficiency and class II, mostly malignant and predisposing to polycythemia and cancer development. This evidence concerns the gene EGLN1 and cancer.